Why TIME’s recognition matters for Ingevity stock

Ingevity (NGVT) recently appeared on TIME’s list of America’s Best Companies 2026, highlighting employee satisfaction, financial performance, and sustainability transparency. For investors, this recognition raises questions about how these factors align with the current valuation.

Over the past year, Ingevity’s share price has shown stronger medium term momentum than recent trading suggests, with the stock down over the past week and month but posting an 11.95% 90 day share price return and a 23.13% year to date share price return. The 1 year total shareholder return of 34.14% and 3 year total shareholder return of 43.89% indicate that investors who stayed invested have seen meaningfully different outcomes from short term traders, as the market reassesses the balance between growth potential and risk following recognitions like the TIME award.

If this kind of rerating story interests you, it can be useful to see which other companies are drawing attention as future compounders through resilient business models such as the 21 top founder-led companies

Ingevity now carries both a TIME endorsement and a strong recent share price run, yet the stock has also pulled back over the past month. Is this still a strong business offered at a sensible price today?

Most Popular Narrative: 16.9% Undervalued

The most followed narrative values Ingevity at $89 per share, compared with the latest close of $73.99. It frames the current price as a discount that depends on confident assumptions about future cash generation.

Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Want to see what this margin story really hinges on. The narrative pulls together profit recovery, richer mix and a future earnings multiple that implies a very different business profile. Curious which specific revenue and margin paths have to line up to reach that fair value.

Result: Fair Value of $89 (UNDERVALUED)

However, Ingevity’s rerating story still faces pressure from APT margin uncertainty and exposure to weaker industrial and automotive demand, which could undermine the current 16.9% undervaluation narrative.

Another View on Ingevity’s Valuation

The earlier narrative leans on future earnings and a target P/E of 9.7x to argue that Ingevity could be undervalued at $73.99 versus a $89 fair value. Using today’s P/E of 100.9x, the picture looks very different. The stock trades well above the US Chemicals industry at 26.8x, the peer average at 27.6x, and even the fair ratio of 33x that the market could move toward over time. That gap leaves far less room for error if earnings or margins do not match expectations, so how comfortable are you with paying such a premium on today’s earnings power?

Next Steps

With both optimism and concern running through this Ingevity story, it makes sense to check the numbers yourself and decide quickly where you stand. A useful starting point is to weigh the 4 key rewards and 3 important warning signs

Looking for more investment ideas beyond Ingevity?

If you stop with Ingevity, you could miss other opportunities that fit your style. Use the Simply Wall St Screener to quickly surface focused, data driven ideas.

• Target potential mispricings by scanning for companies that combine quality metrics with attractive valuations through the 50 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that offer higher yields with resilient profiles using the 11 dividend fortresses.
• Prioritise resilience by checking companies that pass strict balance sheet and fundamentals filters through the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.